cobas® liat Bordetella panel

nucleic acid test
IVD For in vitro diagnostic use.

A mother holds her crying baby who is being examined by a doctor using a stethoscope

Rapid, accurate diagnostic solutions. Bordetella detection made easy.

Pertussis (whooping cough) cases have risen in recent years, yet current Bordetella tests are primarily intended for laboratory use. There is a critical need for Point of Care molecular diagnostic tests that can quickly and accurately identify Bordetella species, including B. pertussis, in near-patient settings, such as primary care clinics. This is essential to ensure timely, effective patient care and disease control.

The global pertussis testing gap

A world map of diverse human figures representing the number of patients with pertussis-like symptoms who should be tested

How many patients should be tested for pertussis?

~75.5 M patients worldwide who present with pertussis-like symptoms should be tested each year1

Read more
A global map made of numerous diverse human figures representing the 8 million people actually tested for pertussis

How many patients are tested?

But only ~8.3 M actually get tested1

Read more
A handful of diverse figures represent the few accurate pertussis tests performed annually

How many patients are tested using gold-standard PCR?

And of those, only ~1 M PCR-accurate pertussis tests are performed each year1

Read more
Benefits at a glance

Benefits at a glance

cobas liat Bordetella panel clinical performance2

View full table

cobas liat Bordetella panel clinical performance2

 

PPA (95% CI)

NPA (95% CI)

LoD* (CFU/mL)

B. pertussis

97.8% (93.7–99.2)

99.9% (99.4–100.0)

36–43

B. parapertussis

98.6% (94.9–99.6)

99.8% (99.2–99.9)

32–36 

B. holmesii 

100.0% (97.3–100.0)

99.7% (99.0–99.9)

21–34

PPA = Positive Percent Agreement, NPA = Negative Percent Agreement, CI = Confidence Interval, LoD = Limit of Detection
*Strain references: B. pertussis: A639 & E431; B. parapertussis: E838 & A747; B. holmesii: F061 & 51541

cobas liat Bordetella panel test specifications

View full table

cobas liat Bordetella panel test specifications

Instrument

cobas® liat analyzer

Targets

B. pertussis
B. parapertussis

B. holmesii

Registration

CE-IVD

Sample type

Nasopharyngeal (NPS)

Collection media

UTM, VTM, and Liquid Amies

Sample extraction

Fully automated and integrated

Technology

Real-time PCR

Control

Internal sample processing control, positive and negative controls

Time to result

~15 minutes

Reagents

Ready-to-use,
pre-packed tube format

Kit storage

2–8°C

Use left and right arrow keys to scroll between the tabs

Overview

Ordering information

error errorMessage
Sorry, we couldn't find the content you are looking for
Please try again later

Compatible products

No products found for this filter.
No products found for this filter.

Related products

Contact us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

References

  1. Boston Healthcare Associates. BHA Roche LIAT Market Forecast Model: BHA, 2019.
  2. F. Hoffman-La Roche Ltd. cobas® liat Bordetella panel nucleic acid test CE/IVD Instructions for use 10180366190 -01 EN